Characteristics

Number

Partial response

Stable

Progressive

P-value

Over all

106

51

47

8

Age

≤60

44

24 (54.5%)

16 (36.4%)

4 (9.1%)

0.304

>60

62

27 (43.6%)

31 (50.0%)

4 (6.5%)

Performance Status

0 & 1

19

13 (68.4%)

6 (31.6%)

0 (0.0%)

0.092

2 & 3

87

38 (43.7)

41 (47.1%)

8 (9.2%)

Pathology

Squamous cell carcinoma

56

21 (37.5%)

30 (53.6%)

5 (8.9%)

0.230

Adenoc arcinoma

37

23 (62.2%)

12 (32.4%)

2 (5.4%)

Large cell carcinoma

13

7 (53.8%)

5 (38.5%)

1 (7.7%)

Grade

G2

59

31 (52.5%)

27 (45.8%)

1 (1.7%)

0.039

G3

47

20 (42.6%)

20 (42.6%)

7 (14.9%)

T-stage

T2

31

19 (61.3%)

9 (29.0%)

3 (9.7%)

0.109

T3

66

30 (45.5%)

31 (47.0%)

5 (7.6%)

T4

9

2 (22.2%)

7 (77.8%)

0 (0.0%)

Radical treatment type (62/106)

Radical radiotherapy

2

1 (50.0%)

1 (50.0%)

0 (0.0%)

0.324

Concomitant chemo-radiotherpy

28

22 (78.6%)

6 (21.4%)

0 (0.0%)

Sequential chemo-radiotherpy

32

19 (59.4%)

10 (31.2%)

3 (9.4%)

Treatment type (Radical vs. Palliative)

Palliative treatment

44

9 (20.5%)

30 (68.2%)

5 (11.4%)

<0.001

Radical treatment

62

42 (67.7%)

17 (27.4%)

3 (4.8%)

Hemoglobin

<11 mg/dl

26

6 (23.1%)

16 (61.5%)

4 (15.4%)

0.008

≥11 mg/dl

80

45 (56.2%)

31 (38.8%)

4 (5.0%)

Radiotherapy technique

2D

91

42 (46.2%)

41 (45.1%)

8 (8.8%)

0.386

3D

15

9 (60%)

6 (40%)

0 (0%)

Mass size

<7 cm

41

28 (68.3%)

10 (24.4%)

3 (7.3%)

0.002

>7 cm

65

23 (35.4%)

37 (56.9%)

5 (7.7%)